Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is developing a dual approach to tackle two major neurological challenges: multiple sclerosis (MS) and the acute effects of alcohol intoxication. The company's pipeline includes Lucid-MS, a patented new chemical entity for MS, and unbuzzd, a dietary supplement designed to support alcohol metabolism and reduce hangover symptoms.
Multiple sclerosis affects an estimated 2.9 million people worldwide, with about one million cases in the United States. The disease is most commonly diagnosed between ages 20 and 50, with a mean age of 32 globally, and affects women at roughly twice the rate of men. Existing therapies often fall short, leaving patients with limited options. Lucid-MS takes a fundamentally different approach from current treatments, and its phase 2 development is supported by an ongoing imaging collaboration with Massachusetts General Hospital. This partnership aims to better understand the drug's effects on the brain and potentially accelerate its path to market.
In addition to MS, Quantum BioPharma is addressing the acute cognitive and physiological effects of alcohol with unbuzzd. This proprietary dietary supplement is formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. The product targets a widespread issue—alcohol misuse and its consequences—offering a potential solution for millions who experience hangovers or seek to mitigate the effects of alcohol.
The company's focus on these two areas highlights the significant unmet need in neurological disorders. For MS, the lack of disease-modifying therapies that effectively halt progression underscores the importance of Lucid-MS. For alcohol intoxication, unbuzzd addresses a common but often overlooked health concern. Quantum BioPharma's pipeline could provide new options for patients and consumers alike.
For more information, see the full terms of use and disclaimers on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer. The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law.
